August 2, 2021
Ono Pharmaceutical’s April-June group sales rose 16.6% over the previous year thanks to growth driven by the label expansions of its flagship PD-1 inhibitor Opdivo (nivolumab) and its SGLT2 inhibitor Forxiga (dapagliflozin). According to its earnings report released on July...read more